Fontem Ventures Comments on Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA’s ongoing scientific investigation of potential safety issue related to seizures reported following e-cigarette use, particularly in youth and young adults05.04.19
Charlotte, April 5, 2019— We are deeply concerned by FDA Commissioner Dr. Scott Gottlieb’s statements* on April 3. Fontem Ventures’ mission is to create something better for the world’s adult smokers. We are evaluating the Commissioner’s statements and underpinning safety reports in detail.
“We routinely capture and assess any consumer complaints about our products. To date, we are unaware of any reports of our consumers suffering seizures as a result of, or in connection with, using our blu products. Our products undergo robust scientific testing and we hold ourselves to high product quality, safety and manufacturing standards. We continuously monitor and assess the scientific and medical literature in relation to vaping, and our products specifically. We welcome the opportunity to assess the results of the FDA’s investigation when it is complete,” said Joseph Thompson, Director Group Science for Imperial Brands.
We are concerned that broad statements, such as these, could prevent current US adult cigarette smokers from choosing less harmful alternatives. As the FDA embarks on this study, we hope they act swiftly. We are fully prepared to assist the FDA in addressing this concern and are eager to read their results.
*In the reports the FDA received, some vapers reported a prior history of seizures and some reported they had used other substances such as marijuana or amphetamines along with e-cigarettes.